ADMA Biologics (ADMA) Q3 2026 Earnings Call Transcript
ADMA reported third-quarter 2026 revenue of $141.1 million. [[fact:fact-okzq563w8]] ASCENIV third-quarter revenue was $124.7 million, up 31% year over year and 21% sequentially. [[fact:fact-i86kp379f]] Third-quarter adjusted EBITDA was $77.3 million, up 32% year over year and 25% sequentially. [[fact:fact-56oic0xuh]] The company raised its minimum full-year adjusted EBITDA guidance from $265 million to $275 million. [[fact:fact-tusiqj14p]] ADMA reiterated its 2026 full-year revenue guidance of at least $530 million. [[fact:fact-wiq1q1v4l]] Days sales outstanding rose to 110 days, above the company's target range of 90 to 105 days. [[fact:fact-dgld5qwtq]]
ADMA Biologics CEO Says Star Drug ASCENIV Is Just Getting Started
ADMA Biologics stock surges 23% after beating Q3 2026 earnings, led by a 31% rise in ASCENIV demand and strong margins.
ADMA shares jump after Q3 results; earnings beat consensus, revenue guidance below consensus
After ADMA reported Q3 on Nov. 4, shares rose 28.24% to $13.44 in after-hours trading, Benzinga reported Nov. 5. Q3 adjusted EPS was $0.23 vs. $0.20 consensus; revenue was $141.1M vs. $138.12M. FY2026 revenue guidance remained at least $530M, below $535.35M consensus; minimum adjusted EBITDA guidance rose to $275M.
ADMA Biologics FY2026 Revenue expected to be more than $530.000M vs $535.360M Est
ADMA Biologics FY2026 Revenue expected to be more than $530.000M vs $535.360M Est(摘要待生成)
ADMA Biologics Reports Third Quarter 2026 Financial Results
ADMA Biologics, Inc. announced its financial results for the third quarter of 2026, reporting adjusted earnings per share of $0.23 and revenue of $141.1 million.
ADMA reports Q3 2026 results; raises adjusted earnings outlook
On Nov. 4, ADMA reported Q3 revenue of $141.1M (+5% YoY), ASCENIV revenue of $124.7M (+31%), GAAP net income of $49.9M (+37%) and gross margin of 71%; BIVIGAM revenue fell to $15.4M from $23.8M. It maintained FY2026 revenue guidance of at least $530M and raised adjusted net income and EBITDA outlooks to at least $180M and $275M.
ADMA Biologics 8-K (2.02, 9.01): reported results of operations
ADMA Biologics reported third-quarter 2026 revenue of $141.1 million and net income of $49.9 million, with ASCENIV revenue up 31% to $124.7 million; it reiterated revenue guidance of at least $530 million and raised minimum adjusted net income and EBITDA outlook to $180 million and $275 million.
Why Is ADMA Biologics Stock Soaring Thursday? - ADMA Biologics (NASDAQ:ADMA) - Benzinga
Why Is ADMA Biologics Stock Soaring Thursday? - ADMA Biologics (NASDAQ:ADMA) Benzinga
Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13
Cantor Fitzgerald Maintains Neutral on ADMA Biologics, Raises Price Target to $13(摘要待生成)
ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M Estimate
ADMA Biologics Q3 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $141.102M Beat $138.190M Estimate(摘要待生成)